Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients.
Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients. is a NA clinical asset sponsored by Sahlgrenska University Hospital in Non-alcoholic Fatty Liver Disease, Morbid Obesity. SEO and diligence focus: Ursodeoxycholic Acid (UDCA), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Non-alcoholic Fatty Liver Disease
Modality: small molecule
Target: Ursodeoxycholic Acid (UDCA)
Sponsor: Sahlgrenska University Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Ursodeoxycholic Acid (UDCA)
View original source fields
Condition raw: Non-alcoholic Fatty Liver Disease, Morbid Obesity
Condition normalized: Non-alcoholic Fatty Liver Disease, Morbid Obesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Ursodeoxycholic Acid (UDCA)
Target normalized: Ursodeoxycholic Acid (UDCA)